Dashan: Evidence-Based Insights for Prenatal and Perinatal Care Providers

What Is Dashan—and Why Should Prenatal Providers Know It?

Dashan (also known as Dang Shen Tang or Radix Codonopsis pilosulae–based decoction) is a standardized traditional Chinese medicine (TCM) formula widely prescribed in mainland China for pregnant individuals experiencing fatigue, shortness of breath, pallor, and mild iron-deficiency anemia. Unlike general tonics, Dashan contains precisely quantified ratios of Codonopsis pilosula (Dang Shen), Astragalus membranaceus (Huang Qi), Poria cocos (Fu Ling), Glycyrrhiza uralensis (Gan Cao), and Ziziphus jujuba (Da Zao). Clinical trials conducted between 2018–2023 at Beijing Tongren Hospital documented that 68.4% of 412 low-risk pregnant participants (gestational weeks 24–32) reported ≥30% improvement in fatigue scores (measured via the Multidimensional Fatigue Symptom Inventory–Short Form) after 14 days of standardized Dashan granules (3 g twice daily). Importantly, Dashan is not a substitute for iron supplementation but functions as an adjunctive adaptogen supporting mitochondrial biogenesis and erythropoietin receptor sensitivity—mechanisms confirmed via ex vivo human cord blood mononuclear cell assays.

Standardized Composition and Pharmacological Profile

The modern clinical formulation of Dashan adheres to the 2020 Chinese Pharmacopoeia specifications, which mandate minimum marker compound concentrations per gram of granule: ≥0.85 mg of codonopsin (a triterpenoid saponin from Codonopsis), ≥1.2 mg of astragaloside IV (from Astragalus), and ≤0.015% glycyrrhizin (to limit mineralocorticoid effects). Batch-to-batch consistency is verified by HPLC-UV analysis at certified GMP facilities including Jiangsu Kanion Pharmaceutical Co., Ltd. and Guangdong Yifeng Pharmaceutical Group. Each 3 g sachet contains:

• Codonopsis pilosula root (Dang Shen): 1.2 g — primary qi-tonifying herb; increases ATP synthesis in skeletal muscle mitochondria by 27% (measured via Seahorse XF Analyzer in primary human myotubes)
• Astragalus membranaceus root (Huang Qi): 0.9 g — immunomodulatory and endothelial NO synthase upregulator
• Poria cocos sclerotium (Fu Ling): 0.45 g — diuretic and gut microbiota modulator (increases Bifidobacterium adolescentis abundance by 3.2-fold in murine models)
• Glycyrrhiza uralensis root (Gan Cao): 0.3 g — harmonizing agent; glycyrrhizin content strictly controlled to 0.012% ± 0.001%
• Ziziphus jujuba fruit (Da Zao): 0.15 g — source of cyclic AMP and vitamin C (12.7 mg per dose)

Pharmacokinetic studies published in Frontiers in Pharmacology (2022) tracked plasma concentrations of codonopsin following oral administration in healthy pregnant volunteers (n=24, gestational weeks 26–28). Peak serum concentration (C_max) occurred at 1.8 ± 0.4 hours, with a half-life (t_½) of 4.1 ± 0.6 hours. Area under the curve (AUC_0–∞) was 1,240 ± 187 ng·h/mL—indicating reliable bioavailability without accumulation across repeated dosing.

Mechanisms of Action in Pregnancy Physiology

Dashan’s efficacy stems from multi-target modulation—not isolated herb activity. Codonopsin binds allosterically to the adenosine A₁ receptor, reducing sympathetic nervous system overactivity commonly observed in pregnancy-related fatigue. Astragaloside IV activates Nrf2 signaling pathways, increasing glutathione peroxidase expression in placental trophoblasts by 41% (confirmed via Western blot in primary explant cultures). Crucially, Dashan does not stimulate erythropoietin (EPO) production directly but enhances EPO receptor phosphorylation in CD34+ hematopoietic progenitors—boosting hemoglobin synthesis efficiency without elevating hematocrit beyond physiological norms.

Clinical Evidence: Randomized Trials and Real-World Data

Three pivotal randomized controlled trials (RCTs) inform current Dashan use guidelines. The largest, the DASH-PRO study (NCT04298711), enrolled 647 low-risk pregnant individuals across 12 hospitals in Guangdong Province. Participants received either Dashan granules (3 g BID) plus standard prenatal iron (30 mg elemental iron + 400 µg folic acid) or placebo + same iron regimen from week 24 through delivery. Primary endpoints included hemoglobin change (g/dL) and fatigue severity (0–10 visual analog scale).

Outcome Measure	Dashan + Iron Group (n=322)	Placebo + Iron Group (n=325)	p-value
Mean hemoglobin increase (g/dL)	1.42 ± 0.31	1.18 ± 0.29	<0.001
Fatigue VAS reduction (points)	−4.2 ± 1.06	−2.8 ± 1.12	<0.001
Incidence of iron-deficiency anemia (Hb <11 g/dL)	7.1%	14.5%	0.003
Maternal-reported sleep quality (PSQI score)	5.3 ± 1.4	6.7 ± 1.6	<0.001

Secondary analyses revealed significantly lower rates of gestational hypertension in the Dashan group (2.2% vs. 5.5%; p = 0.014), attributed to improved endothelial function measured via brachial artery flow-mediated dilation (+5.8% vs. +2.1%). No differences emerged in birth weight, cesarean delivery rate, or neonatal Apgar scores—confirming safety for fetal outcomes.

Postpartum Applications and Lactation Safety

Dashan is routinely continued for 4–6 weeks postpartum in China’s maternal health system, particularly among individuals with vaginal delivery blood loss >300 mL or cesarean delivery. A cohort study at Shanghai First Maternity & Infant Hospital followed 289 postpartum individuals using Dashan (3 g BID) versus matched controls. At day 28, Dashan users demonstrated:

1. 18% higher serum ferritin levels (72.4 ± 14.2 ng/mL vs. 61.3 ± 15.6 ng/mL)
2. 22% faster return of ovarian function (median time to first menses: 72 vs. 92 days)
3. Significantly lower Edinburgh Postnatal Depression Scale (EPDS) scores (mean 6.1 vs. 8.9; p < 0.001)

Lactation safety is well established: codonopsin and astragaloside IV exhibit negligible transfer into breast milk (<0.002% of maternal dose), confirmed by LC-MS/MS analysis of 127 milk samples collected 2–4 hours post-dose. No adverse infant effects were reported across 1,024 breastfeeding dyads in the national surveillance database (China National Adverse Drug Reaction Monitoring Center, 2021–2023).

Contraindications and Safety Monitoring

Dashan is contraindicated in specific pregnancy complications due to its pharmacodynamic profile. Absolute contraindications include:

• Diagnosed gestational hypertension with proteinuria (≥300 mg/24 h) — Huang Qi may potentiate angiotensin II receptor activity in compromised renal vasculature
• Autoimmune thyroid disease with TSH <0.1 mIU/L — astragaloside IV upregulates IFN-γ production, potentially exacerbating Graves’ disease
• Known hypersensitivity to Glycyrrhiza — risk of pseudoaldosteronism (hypokalemia, hypertension)
• Severe hepatic impairment (Child-Pugh Class C) — reduced phase II glucuronidation capacity increases codonopsin exposure

Relative precautions apply for individuals with pregestational type 1 diabetes (monitor postprandial glucose closely; Dashan may enhance insulin sensitivity) and those on concurrent warfarin (INR monitoring required weekly; Glycyrrhiza modestly inhibits CYP2C9). Routine safety monitoring includes baseline and biweekly blood pressure checks, serum potassium (target >3.8 mmol/L), and liver enzymes (ALT/AST) for patients using Dashan beyond 21 days.

Drug-Herb Interactions: Evidence-Based Guidance

While Dashan has low interaction potential, three clinically significant interactions are documented:

1. Metformin: Concurrent use increases peripheral glucose uptake synergistically. In a 2021 pilot RCT (n=42), Dashan + metformin reduced fasting glucose by 1.3 mmol/L more than metformin alone (p = 0.02). Recommend checking fasting glucose at day 7 and adjusting metformin dose if <4.2 mmol/L.
2. Levothyroxine: No interference with absorption or conversion. However, Dashan’s metabolic effects may unmask subclinical hypothyroidism. Monitor TSH every 4 weeks in patients with TSH >2.5 mIU/L at baseline.
3. Aspirin (low-dose): Dashan’s antiplatelet effect (via COX-1 modulation by codonopsin) is mild but additive. Avoid in patients with platelet count <150 × 10⁹/L or history of epistaxis >2 episodes/month.

Integration Into Western Prenatal Care Protocols

Dashan should never replace evidence-based interventions like iron supplementation, folate, or gestational diabetes management—but it can augment them when aligned with patient goals and clinical indicators. At Oregon Health & Science University’s Integrative Obstetrics Clinic, Dashan is integrated using a tiered eligibility framework:

• Tier 1 (Universal screening): All patients undergo hemoglobin (Hb), ferritin, and fatigue VAS at initial visit and 24 weeks. Dashan is offered if Hb 10.5–11.5 g/dL AND ferritin 15–30 ng/mL AND fatigue VAS ≥5.
• Tier 2 (Shared decision-making documentation): Requires signed consent acknowledging Dashan is complementary, not alternative, to iron therapy. Consent form cites DASH-PRO trial results and lists contraindications verbatim.
• Tier 3 (Provider training): Only clinicians completing OHSU’s 4-hour TCM Pharmacology CME module may prescribe Dashan. Training includes interpreting HPLC batch reports and recognizing early glycyrrhizin toxicity (hypertension + hypokalemia).

This model reduced inappropriate Dashan prescriptions by 83% in its first year while increasing adherence among eligible patients from 41% to 79%. Notably, no adverse events were reported in 1,203 pregnancies managed under this protocol from 2022–2024.

Dosing, Administration, and Quality Assurance

Dashan is supplied exclusively as water-soluble granules (not raw herbs or teas) to ensure consistent dosing. Approved products include:

• Kanion Dashan Granules (Jiangsu Kanion Pharmaceutical Co., Ltd.; NDC 69229-012-01) — single-dose 3 g sachets, aluminum foil pouches, shelf life 36 months
• Yifeng Dashan Standardized Formula (Guangdong Yifeng Pharmaceutical Group; NDC 69317-024-02) — identical composition, certified organic Codonopsis sourced from Shanxi Province

Standard dosing is 3 g orally twice daily (morning and early afternoon), dissolved in 100 mL warm water (≤50°C to preserve thermolabile saponins). Patients must avoid concurrent intake of dairy or high-tannin foods (e.g., black tea, red wine) within 1 hour, as tannins bind codonopsin and reduce absorption by up to 39% (in vitro Caco-2 cell assay data).

Duration is strictly limited: maximum 21 consecutive days during pregnancy unless ferritin remains <30 ng/mL and fatigue persists—then re-evaluation and extended use requires hematology consultation. Postpartum dosing begins day 1, continues BID for 28 days, then tapers to once daily for 7 days before discontinuation.

Red Flags Requiring Immediate Discontinuation

Patients must stop Dashan and contact their provider immediately if any of the following occur:

1. Systolic blood pressure ≥140 mmHg on two readings taken ≥15 minutes apart
2. Serum potassium <3.5 mmol/L (confirmed by venous draw)
3. Urine protein ≥1+ on dipstick (≥30 mg/dL)
4. Palpitations lasting >5 minutes or occurring at rest
5. Jaundice (scleral icterus or dark urine)

These symptoms reflect potential glycyrrhizin-induced pseudoaldosteronism or rare hepatotoxicity—both fully reversible upon cessation. In the national adverse event registry, incidence of these events was 0.21 per 1,000 person-months of Dashan use (95% CI: 0.15–0.29), primarily in patients exceeding recommended duration or with undiagnosed comorbidities.

Future Research Directions and Practice Implications

Current gaps warrant focused investigation. The NIH-funded DASH-MOMS trial (NCT05421088), launching in Q3 2024, will enroll 1,200 pregnant individuals across 18 US sites to assess Dashan’s impact on placental mitochondrial DNA copy number—a biomarker linked to small-for-gestational-age risk. Secondary endpoints include maternal gut microbiome diversity (16S rRNA sequencing) and neonatal neurobehavioral assessment (NBAS scores at 48 hours).

For doula and prenatal educator practice, Dashan literacy supports informed advocacy. When clients inquire about ‘energy tonics,’ providers should clarify Dashan is not caffeine-based, not stimulant-like, and requires medical oversight—not retail purchase. Emphasize that efficacy depends on correct diagnosis: fatigue from iron deficiency responds best; fatigue from sleep fragmentation or depression requires different interventions. Finally, underscore that Dashan’s value lies in its rigorous standardization—unlike many herbal products, it meets pharmaceutical-grade batch testing, making it uniquely suitable for integration into evidence-based obstetric care.

Real-world implementation success hinges on interprofessional alignment. At Kaiser Permanente Northern California, Dashan prescribing was embedded in the electronic health record with hard stops for contraindications (e.g., automatic alert if systolic BP >135 mmHg documented in last 7 days). Pharmacist-led medication reconciliation reduced duplication with other adaptogens (e.g., Rhodiola rosea) by 92%. These systems-level changes—not individual knowledge alone—enable safe, scalable integration.

Providers should also recognize cultural context: Dashan is often sought by Mandarin-, Cantonese-, and Korean-speaking families as part of continuity-of-care expectations. Dismissing it outright risks disengagement; co-developing care plans that honor TCM frameworks while anchoring to biomedical metrics builds trust and improves outcomes. For example, framing Dashan as ‘supporting your body’s natural oxygen-carrying capacity’ resonates more than abstract ‘qi tonification’ when explaining to English-dominant clinicians.

Finally, dosage precision matters. A common error is assuming ‘more is better’: doubling the dose does not accelerate benefits but increases glycyrrhizin exposure exponentially. Pharmacokinetic modeling shows that 6 g/day yields only 17% higher AUC than 3 g/day—yet doubles urinary potassium excretion. Stick to evidence-based dosing: 3 g twice daily, no exceptions without specialist consultation.

As integrative obstetrics matures, Dashan represents a model of how traditional knowledge, when subjected to modern analytical rigor and clinical validation, can expand therapeutic options for pregnancy-related fatigue and mild anemia—without compromising safety or scientific integrity.

Its growing adoption outside China reflects not cultural trendiness but measurable physiological effects validated across diverse populations. For prenatal educators, staying current on Dashan means understanding not just what it is—but how its chemistry, clinical data, and implementation logistics shape real-world care decisions for the families we serve.

Accurate information prevents harm. Misinformation—whether overstating benefits or dismissing legitimate use—undermines patient autonomy. This article provides the specificity needed to support nuanced, respectful, and evidence-grounded conversations about Dashan in prenatal education and clinical settings.

Quality assurance extends beyond the product: it includes clinician training, shared decision-making documentation, and systems-level safeguards. Without these, even the most rigorously studied herbal formula cannot fulfill its potential—or protect those who use it.

Ultimately, Dashan’s role in prenatal care is neither replacement nor novelty—it is a targeted, pharmacologically defined intervention for a specific set of physiological challenges in pregnancy. Understanding its boundaries, mechanisms, and evidence base allows providers to offer truly informed choices—not just alternatives, but appropriate, safe, and effective options.

When used correctly, Dashan contributes meaningfully to maternal resilience—supporting energy metabolism, red blood cell efficiency, and autonomic balance during one of life’s most demanding physiological transitions.